Propanc Biopharma Receives Certificate of Grant for “Proenzymes Composition” Patent from Japanese Patent Office
Certificate of Grant Received for “Cancer Treatment” Patent from
The proenzymes composition patent is an important part of the IP portfolio as it covers possible future clinical dosage ranges for PRP as the Company advances into early-stage clinical development.
The cancer treatment patent describes a method to target and eradicate cancer stem cells (CSCs) using PRP which minimizes the progression of cancer in a patient. Currently, progression, or spread of cancer, called metastatic cancer, is the main cause of patient death for sufferers.
“We are building an extensive and mature intellectual property portfolio around the use of proenzymes as a novel treatment for advanced solid tumors,” said Mr.
About PRP:
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells. Examples include pancreatic, ovarian, kidney, breast, brain, prostate, colorectal, lung, liver, uterine, and skin cancers. Orphan Drug Designation status of PRP has been granted from the
To view the Company’s “Mechanism of Action” video on the Company’s lead asset, PRP, please click on the following link: http://www.propanc.com/news-media/video.
About
The Company’s novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body’s primary defense against cancer.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the planned studies and market projections described above and the successful execution of the Company’s business strategy. The Company’s actual results could differ materially from those anticipated in these forward-looking statements because of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process; the availability of financing; the Company’s ability to implement its long range business plan for various applications of its technology; the Company’s ability to enter into agreements with any necessary business partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company’s technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company’s reports filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625873108/en/
Investor Relations and Media Contacts:
irteam@propanc.com
+61-3-9882-0780
Source: